Extent of disease:\r\n* Patients with non-metastatic and metastatic disease are eligible\r\n* Initially unresectable patients, with or without metastatic disease, are eligible as long as there is a commitment at enrollment to resect the primary tumor
Patients with more than  discrete locations of extra-cranial metastatic disease after first-line systemic therapy requiring more than  radiation/surgery plans to cover these distinct metastatic disease entities.
Have a history of an invasive metastatic disease, except for the following:
Individuals with a history of invasive metastatic disease are eligible if they have been disease free for at least  years and are deemed by the Investigator to be at low risk for recurrence of that metastatic disease;
Known spinal cord compromise or instrumentation due to metastatic disease. Radiation therapy for metastatic disease is allowed.
Metastatic CRPC
Known metastatic disease
Any patient with metastatic disease.
Patient does not have metastatic disease
Confirmed metastatic disease
PHASE IB: =<  lines of prior systemic therapy for metastatic disease (if patients have metastatic disease)
Has at least  identified sites of metastatic disease by imaging.
Diagnosis of metastatic disease
Presence of metastatic disease
Known metastatic disease
Metastatic disease
Prior radiation treatment for metastatic disease
For patients with metastatic disease:
N M disease
Known metastatic disease
Any metastatic disease
Widely metastatic disease (oligometastatic disease acceptable)
Metastatic disease.
Patients may have received one prior hormonal treatment for metastatic disease
Metastatic disease or local-regional disease that is considered not resectable for cure
Has metastatic disease
Patients with more than >=  metastatic lung lesions or any one lesion greater than  cm and/or extensive metastatic disease outside the chest
Patient has had at least one prior systemic therapy for metastatic disease
Has metastatic disease
Metastatic
Metastatic disease
Patients must not have known metastatic disease
Patients with metastatic disease will not be excluded
Patients with metastatic disease
The subject has metastatic disease at the time of screening
No metastatic disease (M)
Patients must have received at least one prior therapy for metastatic disease to be eligible
Patients with histologically confirmed metastatic melanoma, metastatic non-small cell lung cancer, metastatic breast cancer, or metastatic pancreatic adenocarcinoma relapsed or refractory to therapy as outlined below or patients with these malignancies who have declined, are or have become unable to tolerate (e.g. progressive chemotherapy-associated peripheral neuropathy), or were not eligible for standard therapy\r\n* Metastatic melanoma patients at any line of therapy\r\n* Metastatic non-small cell lung cancer patients who have relapsed or are refractory to at least one line of systemic anti-cancer therapy for metastatic disease, including cytotoxic chemotherapy or targeted therapy\r\n* Metastatic breast cancer patients who have relapsed or are refractory to at least one line of systemic anti-cancer therapy for metastatic disease, such as cytotoxic chemotherapy, hormonal therapy, or targeted therapy\r\n* Metastatic pancreatic adenocarcinoma who have relapsed or are refractory to at least one line of systemic anti-cancer therapy for metastatic disease, such as cytotoxic chemotherapy or targeted therapy
Presence of metastatic disease on scans
Known metastatic disease
Known metastatic disease
Presence of metastatic disease
Known metastatic disease
Multi-focal or metastatic disease
Known metastatic disease
Metastatic disease on pretreatment imaging
There must be documentation that the patient has evidence of measurable metastatic breast cancer. Histologic confirmation of metastatic disease is not required.
Known metastatic disease
Metastatic disease
History, presence, or suspicion of metastatic disease
Patients with metastatic disease
Metastatic disease
Presence of metastatic disease
No prior chemotherapy for metastatic disease
Histological or cytological diagnosis of metastatic CRC excluding known microsatellite instable sub-types, metastatic SCCHN or metastatic NSCLC that have progressed or have become intolerant to standard therapy, and whose disease may allow management with other available therapies
Metastatic disease
Patients with Gilbert's disease or known CNS metastatic disease.
Patients with metastatic disease limited to the CNS
Metastatic disease
Metastatic disease or non-testicular primary
Have received at least one prior therapy for metastatic disease
Presence of distant metastatic disease or disease not amenable to radiation treatment
Presence of metastatic disease
Diagnosis of metastatic disease
Patients with metastatic disease
No more than two prior therapies for metastatic disease
Patients must have metastatic disease
Patient has known nodal or distant metastatic disease; patients with nodal or metastatic disease require systemic chemotherapy; furthermore, they should be excluded from this clinical trial because of their poor overall prognosis
Patients with metastatic disease must have received at least one line of standard of care (SOC) treatment for metastatic disease prior to enrollment
Received prior trastuzumab or chemotherapy for metastatic breast cancer except if patient has CNS as only site of metastatic disease
History of metastatic disease at any time or presence of detectable metastases.
Metastatic disease involving bone with metastatic disease previously confirmed by prior biopsy; or Metastatic disease involving bone previously confirmed on imaging (e.g. CT or MRI) with known (biopsied) primary disease (primary bone cancer is excluded)
Prior systemic therapy for metastatic disease
Have histologically confirmed unresectable or metastatic melanoma having received no more than one prior systemic therapy for the metastatic disease (eg. ipilumamab and/or BRAF inhibitor); unresectable or metastatic smoking-associated NSCLC having received no more than one prior systemic therapy for the metastatic disease (eg standard of care chemotherapy, as appropriate); unresectable or metastatic transitional cell carcinoma of the bladder, urethra, ureter or renal pelvis having received no more than one prior systemic therapy for the metastatic disease.
Have histologically or cytologically diagnosed oligo-metastatic prostate cancer; oligo-metastatic disease is defined to reflect men with low volume disease; specifically, oligo-metastatic disease is defined as less than  extra-pelvic metastases; metastatic lesions may be lymph nodes
Known metastatic disease
Metastatic disease
Have metastatic disease
Metastatic disease
Have metastatic disease
Last treatment for metastatic disease including Trastuzumab in combination with pertuzumab
Patients with metastatic cancer
Documentation of metastatic disease
- sites of metastatic disease able to be targeted by SABR
Prior chemotherapy for metastatic disease
Metastatic disease
No prior chemotherapy for metastatic disease
Prior systemic chemotherapy for metastatic disease
Imaging confirmation of metastatic disease
At least one prior treatment for metastatic disease
Any metastatic disease
Patients with prior surgical resection who develop radiological or clinical evidence of metastatic cancer do not require separate histological or cytological confirmation of metastatic disease unless an interval of >  years has elapsed between the primary surgery and the development of metastatic disease; clinicians should consider biopsy of lesions to establish diagnosis of metastatic disease if there is substantial clinical ambiguity regarding the nature or source of apparent metastases
Patient has known metastatic disease
I . Metastatic disease.
Patients should have at least one organ system involved with distant metastatic disease; if only a single metastatic lesion is present, biopsy is mandatory
OTHER METASTATIC SITES:
Patients with metastatic disease
Presence of extra-cranial metastatic disease
Group A: Metastatic disease, myeloma, lymphoma;
No prior systemic therapy for metastatic disease.
Patients with metastatic disease
Metastatic disease
CNS metastatic disease
Unilobar disease
Patients with known metastatic disease are excluded
Pathologically (histologically or cytologically) confirmed metastatic disease with a new tumor involving or abutting bone that has the clinical and imaging features of metastatic disease\r\n* If the nature of the metastatic disease has been previously documented, index tumor to be treated does not require further documentation (i.e., biopsy)
Treatment with erlotinib prior to developing metastatic disease
Metastatic disease.
Prior systemic therapy for metastatic disease.
Patients must have demonstrated metastatic disease and not received >  lines of chemotherapy for metastatic disease (N/A for phase II)
Presence of metastatic disease to the bone
Metastatic disease on baseline staging scans
The patient has another metastatic cancer disease.
No prior chemotherapy for metastatic disease
Metastatic cancer
Patients with metastatic disease
Have metastatic cancer
Patients with metastatic disease (BREAST ONLY)
Patients with metastatic disease
Presence of metastatic disease
Diagnosis of pathologically confirmed metastatic pancreatic, hepatobiliary, esophageal, or lung cancer, either newly metastatic or metastatic at presentation (M+) and enrollment within  weeks of diagnosis; measurable disease need not be present
Free of macro-metastatic disease
Any spinal cord compromise or instrumentation due to metastatic disease; radiation therapy for metastatic disease is allowed
RENAL CANCER: Starting any systemic therapy for metastatic disease
Presence of metastatic disease
Presence of metastatic disease
Subject with metastatic disease
Known metastatic disease
Informed of metastatic disease within the previous  weeks
No prior therapy for metastatic disease
Presence of metastatic disease
There is no limit to the amount of prior therapy for metastatic disease
Patients with metastatic disease
Metastatic disease
Absence of metastatic disease as documented by radiographic scans
T disease
Patients with metastatic disease
Metastatic disease
Patients with known metastatic disease
Patients with any metastatic disease
Patients with known metastatic disease
Patients with metastatic disease
Have confirmed metastatic disease
Patient: Does not have metastatic disease
Does not have metastatic disease
Patients have either metastatic or non-metastatic lung cancer as defined in history and physical